Amylyx Pharmaceuticals

AMLX Rare disease Lead: Phase 3 7 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-03

Catalyst timeline

AMX0318 IND filing2027AMX0318 IND filing, 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

avexitide

Peptide Target: GLP-1 receptor

Post-Bariatric Hypoglycemia Phase 3 subcutaneous NCT06747468
Congenital Hyperinsulinism

sodium phenylbutyrate and taurursodiol

AMX0035

Small Molecule Target: endoplasmic reticulum stress, mitochondrial dysfunction

Wolfram Syndrome Phase 2 oral NCT05676034

AMX0114

Nucleic Acid Target: calpain-2, CAPN2

Amyotrophic Lateral Sclerosis Phase 1 intrathecal NCT06665165

AMX0318

Peptide Target: GLP-1 receptor

Post-Bariatric Hypoglycemia Preclinical Gubra

Discontinued (1)

AMX0035 — Progressive Supranuclear Palsy · discontinued after discontinuation of AMX0035 for PSP

Biotech Distilled coverage (7)

2026-08-20 UPDATE: Amylyx Pharmaceuticals (AMLX) - The $500 Million Vote of Confidence 🔒 Paid
2026-08-19 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Coin Landed Heads 🔒 Paid
2026-08-17 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Alarm Goes Off Tomorrow 🔒 Paid
2026-08-07 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Binary Has a Date 🔒 Paid
2026-05-08 UPDATE: Amylyx Pharmaceuticals (AMLX) — The Quiet Tells Before the Binary 🔒 Paid
2026-03-28 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Clock Starts Now 🔒 Paid
2026-03-11 Amylyx Pharmacueticals (AMLX) - Scientific Deep Dive for Avexitide and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.